Moberg Pharma’s rights issue of MSEK 100 is oversubscribed – subscription rate 130%
STOCKHOLM, 1 September 2023. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) today announces the outcome of the rights issue of units, consisting of ordinary shares and warrants, with preferential rights for Moberg Pharma’s shareholders (the “Rights Issue”) which was resolved upon by the Board of Directors on 28 June 2023 and approved by an Extraordinary General Meeting on 8 August 2023. The outcome of the Rights Issue shows that subscription with support of unit rights and applications for subscription of units without support of unit rights in